ArticleMolecular and cellular biology2013
Molecular mechanism of SLC5A8 inactivation in breast cancer.
Article in Molecular and cellular biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- A lactylation-related gene signature predicts metastasis and prognosis in breast cancer.Scientific reports · 2025Article
- Innovative gene engineering and drug delivery systems for dendritic cells in cancer immunotherapy.Journal of biomedical science · 2025Review
- MicroRNAs and Their Inhibition in ModulatingInternational journal of molecular sciences · 2025Article
- Exploring the Effects of Metformin on the Body via the Urine Proteome.Biomolecules · 2025Article
- Role of hypermethylated SLC5A8 in follicular thyroid cancer diagnosis and prognosis prediction.World journal of surgical oncology · 2023Article
- Prognostic value ofFrontiers in oncology · 2023Article
- RAD51AP1 Loss Attenuates Colorectal Cancer Stem Cell Renewal and Sensitizes to Chemotherapy.Molecular cancer research : MCR · 2021Article
- Comprehensive analysis of regulation of DNA methyltransferase isoforms in human breast tumors.Journal of cancer research and clinical oncology · 2021Review
- Article
- Article
- A DNA aptamer for binding and inhibition of DNA methyltransferase 1.Nucleic acids research · 2019Article
- Sodium-coupled monocarboxylate transporter is a target of epigenetic repression in cervical cancer.International journal of oncology · 2019Article
- Deficiency of Dietary Fiber inCanadian journal of gastroenterology & hepatology · 2019Article
- Short-Chain Fatty Acid Transporters: Role in Colonic Homeostasis.Comprehensive Physiology · 2017Review
- PSIP1/p75 promotes tumorigenicity in breast cancer cells by promoting the transcription of cell cycle genes.Carcinogenesis · 2017Article
- DM-BLD: differential methylation detection using a hierarchical Bayesian model exploiting local dependency.Bioinformatics (Oxford, England) · 2017Article
- SLC transporters as a novel class of tumour suppressors: identity, function and molecular mechanisms.The Biochemical journal · 2016Review
- Article
- Slc5a8, a Na+-coupled high-affinity transporter for short-chain fatty acids, is a conditional tumour suppressor in colon that protects against colitis and colon cancer under low-fibre dietary conditions.The Biochemical journal · 2015Article
- DNA demethylation and invasive cancer: implications for therapeutics.British journal of pharmacology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 3 countries.
Funding
Abstract
SLC5A8 is a putative tumor suppressor that is inactivated in more than 10 different types of cancer, but neither the oncogenic signaling responsible for SLC5A8 inactivation nor the functional relevance of SLC5A8 loss to tumor growth has been elucidated. Here, we identify oncogenic HRAS (HRAS(G12V)) as a potent mediator of SLC5A8 silencing in human nontransformed normal mammary epithelial cell lines and in mouse mammary tumors through DNMT1. Further, we demonstrate that loss of Slc5a8 increases cancer-initiating stem cell formation and promotes mammary tumorigenesis and lung metastasis in an HRAS-driven murine model of mammary tumors. Mammary-gland-specific overexpression of Slc5a8 (mouse mammary tumor virus-Slc5a8 transgenic mice), as well as induction of endogenous Slc5a8 in mice with inhibitors of DNA methylation, protects against HRAS-driven mammary tumors. Collectively, our results provide the tumor-suppressive role of SLC5A8 and identify the oncogenic HRAS as a mediator of tumor-associated silencing of this tumor suppressor in mammary glands. These findings suggest that pharmacological approaches to reactivate SLC5A8 expression in tumor cells have potential as a novel therapeutic strategy for breast cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.